Frontline Therapy in ALL
Sort by:
Insights from 2025 Tandem Annual Meeting
Tandem 2025 Insights: Management of Steroid Refractory Acute GVHD
FEATURING
David Jacobsohn
- 4 views
- March 10, 2025
Nicholas Short
Clinical Use of MRD in Adult ALL: Recommendations From a Panel of U.S. Experts
- 10 views
- February 28, 2025
GRACE
HSCT & Cell Therapy 101: Overview of Types, Processes, Supportive Care, and Toxicities
FEATURING
Muhammad Salman Faisal
- 21 views
- February 6, 2025
Elisabetta Xue
Identifying Steroid-Refractory or Steroid-Dependent cGVHD and the Role of Ruxolitinib
- 49 views
- January 30, 2025
GRACE
Common Toxicities Associated With Allogeneic HSCT
FEATURING
Muhammad Salman Faisal
- 11 views
- January 30, 2025
Roswell Park Comprehensive Cancer Center
Steroid-Refractory GVHD Updates
FEATURING
Shernan Holtan
- 192 views
- January 24, 2025
City of Hope
Acute GVHD: Demographics, Diagnosis, Pathophysiology, and Advancements in Treatment With Corticosteroids & JAK Inhibitors
FEATURING
Amandeep Salhotra
- 97 views
- January 22, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Ph- ALL
FEATURING
Fadi Haddad
- 162 views
- January 21, 2025
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Ph+ ALL
FEATURING
Fadi Haddad
- 112 views
- January 21, 2025
- 1
ecancer
ASH 2024 Insights: Blinatumomab + Chemo in Newly Diagnosed NCI Standard Risk Pediatric B-ALL - Ph3 COG AALL1731 Trial
FEATURING
Rachel Rau
- 9 views
- January 21, 2025
Louisville Hematology Highlights
2024 Review of Frontline Treatment in ALL
FEATURING
Nicholas Short
- 63 views
- January 21, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Dasatinib + Inotuzumab Ozogamicin-Based Induction for 1L Ph+ ALL
FEATURING
Anand Patel
- 35 views
- December 30, 2024
- 1
Giuseppe Francesco Milone
The Evolving Landscape of cGVHD Treatment Options
- 44 views
- December 27, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in AML, MDS, and ALL
FEATURING
Talha Badar
- 1,223 views
- December 24, 2024
- 6
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in Adult ALL and Implications for Practice
FEATURING
Ryan Cassaday
- 330 views
- December 23, 2024
- 6
University of Illinois Cancer Center
Emerging Induction and Consolidation Regimens in ALL
FEATURING
John Quigley
- 7 views
- December 20, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: COG AALL1731 - Blinatumomab Added to Chemo in Newly Diagnosed NCI Standard Risk Pediatric B-ALL
FEATURING
Sumit Gupta
- 163 views
- December 19, 2024
- 2
